Patents Assigned to Brigham and Women's Hospital
  • Patent number: 10190173
    Abstract: Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: January 29, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Scott Tomlins, Daniel Rhodes, Arul Chinnaiyan, Rohit Mehra, Mark A. Rubin, Xiao-Wei Sun, Sven Perner, Charles Lee, Francesca Demichelis
  • Patent number: 10190119
    Abstract: Disclosed herein are compositions and methods for treating soft-tissue calcification by targeting SLC25A24 and/or SLC25A3.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: January 29, 2019
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Elena Aikawa, Joshua Daniel Hutcheson, Claudia Goettsch, Masanori Aikawa
  • Publication number: 20190022280
    Abstract: The present invention provides compositions and methods for repair and reconstruction of defects and injuries to the cornea.
    Type: Application
    Filed: February 8, 2017
    Publication date: January 24, 2019
    Applicants: The Brigham and Women's Hospital, Inc., Massachusetts Eye and Ear Infirmary
    Inventors: Ali KHADEMHOSSEINI, Nasim ANNABI, Reza DANA, Ahmad KHEIRKHAH
  • Patent number: 10184151
    Abstract: Provided herein are methods of treating a neurodegenerative disorder such as Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) that include administering to a subject at least one inhibitory nucleic acid that decreases the level or activity of microRNA hsa-miR-155.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: January 22, 2019
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Howard Weiner, Oleg Butovsky, Merit Cudkowicz, James Berry
  • Patent number: 10182985
    Abstract: Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: January 22, 2019
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Andrew Bellinger, Shiyi Zhang, Carlo Giovanni Traverso, Robert S. Langer, Stacy Mo, Tyler Grant, Mousa Jafari, Dean Liang Glettig, Angela DiCiccio, Lowell L. Wood, Jr., Philip A. Eckhoff
  • Publication number: 20190010551
    Abstract: The technology described herein is directed to the diagnosis, prognosis, and treatment of kidney fibrosis, e.g., chronic kidney disease.
    Type: Application
    Filed: September 25, 2018
    Publication date: January 10, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vishal S. Vaidya, Florin Craciun, Amrendra K. Ajay
  • Patent number: 10175328
    Abstract: Systems and methods for combined ghost artifact correction and parallel imaging reconstruction of simultaneous multislice (“SMS”) magnetic resonance imaging (“MRI”) data are provided. Dual-polarity training data are used to generate ghost-free slice data, which are used as target data in a reconstruction kernel training process. The training data are used as source data in the reconstruction kernel training. As a result, reconstruction kernels are computed, which can be used to reconstruct images from SMS data in which slice-specific ghosting artifacts are removed.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: January 8, 2019
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL
    Inventors: William Scott Hoge, Jonathan R Polimeni, Kawin Setsompop
  • Publication number: 20190002920
    Abstract: The methods and compositions provided herein improve upon the methods presently used for targeted genomic modification, in part, by removing the requirement for sub-cloning of a sequence complementary to a site selected for genomic modification. The methods and compositions provided herein can be used in place of a standard CRISPR/Cas system to provide simple, fast, and inexpensive targeted modification of a genome. The methods and compositions provided herein can also be used in high-throughput genome editing applications.
    Type: Application
    Filed: April 28, 2016
    Publication date: January 3, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard Sherwood, Mandana Arbab
  • Patent number: 10154977
    Abstract: Described herein are compositions and methods relating to particles comprising at least one component of a cellular-derived microparticle. Aspects of technology described herein relate to compositions and methods for treating inflammation, wounds, and pain.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: December 18, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Lucy V. Norling, Matthew Spite, Jesmond P. Dalli
  • Publication number: 20180355016
    Abstract: Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.
    Type: Application
    Filed: November 17, 2016
    Publication date: December 13, 2018
    Applicants: The Brigham and Women's Hospital, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Vijay K. KUCHROO, Chao WANG, Aviv REGEV, Karthik SHEKHAR
  • Patent number: 10149736
    Abstract: In a method for printing an RFID tag on an object, a deposition mask is applied to the surface of an object. With the deposition mask on the surface of the object, RFID materials are deposited on at least one portion of the surface exposed by aperture(s) in the deposition mask. In particular embodiments, RFID tags can be deposited on medical instruments.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: December 11, 2018
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: Michael J. Smith, Frank L. Hammond, III, Robert J. Wood, Simon G. Talbot
  • Publication number: 20180343839
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: December 6, 2018
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, JAN KRÖNKE, STEVEN A. CARR, NAMRATA D. UDESHI, EMMA FINK
  • Publication number: 20180346988
    Abstract: The present invention relates to the use of ZNF532 inhibitors for the treatment of cancer, in particular cancer with cells that express the ZNF532 protein or harbor the ZNF532-NUT fusion gene. In some embodiments, the cancer is selected from the group consisting of NUT midline carcinoma (NMC), Ewing sarcoma, and head and neck squamous cell carcinoma.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 6, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Christopher Alexander French, Mitzi I. Kuroda, Erica M. Walsh Michel, Artyom A. Alekseyenko
  • Publication number: 20180340022
    Abstract: The methods and uses described herein relate to the treatment of age-related conditions, e.g. by administering an agent that inhibits the interaction of GDF11 and follistatin. In some embodiments, the agent can bind to an epitope of GDF11 as described herein.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 29, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Richard Theodore LEE
  • Publication number: 20180327740
    Abstract: Provided herein is an improved method for performing CRISPR/Cas based screening that is not dependent on viral cloning methods.
    Type: Application
    Filed: November 11, 2016
    Publication date: November 15, 2018
    Applicants: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: David K. Gifford, Nisha Rajagopal, Richard Irving Sherwood
  • Patent number: 10125116
    Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: November 13, 2018
    Assignees: Brandeis University, University of Georgia Research Foundation, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Sivapriya Kirubakaran, Sushil K. Maurya, Boris Striepen, Suresh K. Gorla, Corey R. Johnson, Mandapati Kavitha, Jihan Khan
  • Patent number: 10119168
    Abstract: The technology described herein is directed to the diagnosis, prognosis, and treatment of kidney fibrosis, e.g., chronic kidney disease.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: November 6, 2018
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vishal S. Vaidya, Florin Craciun, Amrendra K. Ajay
  • Patent number: 10119169
    Abstract: Methods for diagnosing and treating Müllerian Adenosarcoma that include detecting the presence of one or more of a mutation in an ATRX gene, and/or a Copy Number Variation (CNV) in a MYBL1, MDM2, HMGA2, and/or CDK4 gene.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: November 6, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Brooke Howitt, Bradley Quade, Marisa Nucci, Lynette Sholl
  • Publication number: 20180311356
    Abstract: Embodiments herein provide for compositions and methods for inhibiting pathological endothelial-to-mesenchymal transition (EndMT), e.g., in endothelial cells and in a mammal. Specially, pathological EndMT can be inhibited by inhibiting CD45, either protein activity or protein expression or both, and optionally also inhibiting TGF-?. Compositions comprising a CD45 inhibitor, a CD45 inhibitor and a TGF-? inhibitor, or a CD45 inhibitor, a TGF-? inhibitor and an anti-fibrosis agent are disclosed.
    Type: Application
    Filed: October 19, 2016
    Publication date: November 1, 2018
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Joyce E. BISCHOFF, Robert A. LEVINE, Elena AIKAWA
  • Patent number: 10111847
    Abstract: Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that fmd use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions fmd use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: October 30, 2018
    Assignees: The Regents of the University of California, The Brigham and Women's Hospital, Inc.
    Inventors: Michael S. Conte, Charles N. Serhan, Tejal A. Desai